This is a preview of subscription content, log in via an institution to check access.
Reference
Pollard M, et al. Cost-effective analysis (CEA) of the current treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC). 108th Annual Meeting of the American Urological Association : abstr. 128, 4 May 2013.
Rights and permissions
About this article
Cite this article
Current treatments for prostate cancer not cost effective. PharmacoEcon Outcomes News 678, 4 (2013). https://doi.org/10.1007/s40274-013-0388-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0388-4